Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Clinical trial NCT07575399 · RECRUITING
Trial details
- NCT number
- NCT07575399
- Sponsor
- Amgen
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-11
- Primary completion
- 2028-01-03
- Enrollment
- 300
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.